Clinical Advisory Board

Wendy Levin, MD
Wendy Levin, MD
Chief Medical Officer, Biofidelity

Dr. Levin is a Hematologist and Oncologist with over 15 years of clinical drug development industry experience, spanning a broad range of early and late targets and disease indications. She completed her undergraduate and graduate studies at the University of California Los Angeles (UCLA, under the guidance of Dr. Dennis J. Slamon), and co-authored the first publications on HER-2/neu in breast and ovarian cancers. She completed her Internal Medicine residency at University of Southern California (LAC + USC), and her Fellowship at the University of Washington/Fred Hutchinson Cancer Research Center. As an Attending Physician University of Washington, she focused on malignant hematology and sarcoma. In her first Industry role at Pfizer, she led the development of the Pfizer Hedgehog inhibitor Daurismo from pre-clinical IND to designing the FDA Registration trial for Daurismo in elderly unfit acute myeloid leukemia (AML). She has since held increasingly responsible roles in both pharma and biotech,  and is the co-author of over 30 publications.

Katherine Ruffner, MD
Katherine Ruffner, MD

Dr. Ruffner is board-certified medical oncologist trained in oncology at the Fred Hutchinson Cancer Research Center/University of Washington. After completing fellowship, where she worked on radioimmunotherapy for the treatment of acute myeloid leukemia, she spent 5 years on faculty at Vanderbilt University in the Hematopoietic Stem Cell Transplant program before leaving academic medicine for industry. She has been a part of the clinical development programs in both small biotechs and large pharma and has contributed to the development of multiple assets that are currently approved for the treatment of cancer, including panitumumab, crizotinib, bosutinib, brentuximab vedotin, and moxetumomab pasudotox. She is the former Chief Medical Officer at Cardiff Oncology.